A1CF | APOBEC1 complementation factor | | | | ![](/images_static/rna_center.gif) | ![](/images/44079/132428_B_8_7_rna_selected_60x60.jpg) | Tissue enhanced |
AADAC | Arylacetamide deacetylase | Enzymes
| ![](/images/2911/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2911/10291_B_8_8_rna_selected_60x60.jpg) | Tissue enhanced |
AADAT | Aminoadipate aminotransferase | Enzymes Mitochondrial proteins
| | ![](/images/37502/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/37502/76141_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
ABAT | 4-aminobutyrate aminotransferase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/41528/91017_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ABCA6 | ATP-binding cassette, sub-family A (ABC1), member 6 | Predicted membrane proteins Transporters
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ABCC6 | ATP-binding cassette, sub-family C (CFTR/MRP), member 6 | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| ![](/images_static/rna_center.gif) | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ACOX2 | Acyl-CoA oxidase 2, branched chain | Enzymes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/38280/80274_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
ACSM1 | Acyl-CoA synthetase medium-chain family member 1 | Enzymes Mitochondrial proteins Predicted membrane proteins
| ![](/images/46291/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images/46291/ihc_cell_selected_60x60.jpg) | ![](/images/46291/102059_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
ACSM3 | Acyl-CoA synthetase medium-chain family member 3 | Enzymes Mitochondrial proteins
| ![](/images/41013/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/41013/84762_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
ADAMTS13 | ADAM metallopeptidase with thrombospondin type 1 motif, 13 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | ![](/images/42014/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/42014/98164_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
ADRA1A | Adrenoceptor alpha 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| ![](/images/29679/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/29678/70371_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
AGMO | Alkylglycerol monooxygenase | Enzymes Predicted membrane proteins
| ![](/images/40332/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/40332/88014_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
AGT | Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| ![](/images/1557/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/1557/4908_B_7_1_rna_selected_60x60.jpg) | Tissue enhanced |
AL358113.1 | Tight junction protein 2 (Zona occludens 2) isoform 1 variant; Uncharacterized protein | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ALDH1L1 | Aldehyde dehydrogenase 1 family, member L1 | Enzymes Plasma proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/36900/72530_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
AMDHD1 | Amidohydrolase domain containing 1 | Enzymes
| ![](/images/39720/ihc_selected_60x60.jpg) | ![](/images/39720/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/39720/85708_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ANGPTL4 | Angiopoietin-like 4 | Plasma proteins Predicted secreted proteins
| ![](/images/33770/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/33770/152718_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
ANGPTL6 | Angiopoietin-like 6 | Plasma proteins Predicted secreted proteins
| ![](/images/41171/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/41171/86054_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
AOX1 | Aldehyde oxidase 1 | Enzymes Plasma proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/40199/88099_A_2_5_rna_selected_60x60.jpg) | Tissue enhanced |
APOC3 | Apolipoprotein C-III | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ARG1 | Arginase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | ![](/images/3595/if_selected_60x60.jpg) | ![](/images/3595/ihc_cell_selected_60x60.jpg) | ![](/images/3595/11122_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ARSE | Arylsulfatase E (chondrodysplasia punctata 1) | Disease related genes Predicted membrane proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ART4 | ADP-ribosyltransferase 4 (Dombrock blood group) | Blood group antigen proteins CD markers Enzymes Predicted membrane proteins Predicted secreted proteins
| ![](/images/40879/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/40879/95140_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ASPDH | Aspartate dehydrogenase domain containing | Enzymes
| ![](/images/42654/ihc_selected_60x60.jpg) | ![](/images/42631/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/42631/96310_B_7_1_rna_selected_60x60.jpg) | Tissue enhanced |
ASPG | Asparaginase homolog (S. cerevisiae) | Enzymes
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ASS1 | Argininosuccinate synthase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | ![](/images/20896/48102_B_2_1_rna_selected_60x60.jpg) | Tissue enhanced |
AZGP1 | Alpha-2-glycoprotein 1, zinc-binding | Cancer-related genes Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/16087/35797_B_1_4_rna_selected_60x60.jpg) | Tissue enhanced |
BCHE | Butyrylcholinesterase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| ![](/images/1560/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/1560/4867_B_8_7_rna_selected_60x60.jpg) | Tissue enhanced |
BCO2 | Beta-carotene oxygenase 2 | Enzymes
| ![](/images/39825/ihc_selected_60x60.jpg) | ![](/images/40695/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/39825/87632_A_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
BLOC1S5-TXNDC5 | BLOC1S5-TXNDC5 readthrough (NMD candidate) | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
C1orf168 | Chromosome 1 open reading frame 168 | | ![](/images/30089/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/30089/65150_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
C2 | Complement component 2 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/16775/38385_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
C2orf72 | Chromosome 2 open reading frame 72 | | ![](/images/44962/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/44962/104572_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
C6orf123 | Chromosome 6 open reading frame 123 | | ![](/images/42587/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42587/93410_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
CBS | Cystathionine-beta-synthase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | ![](/images/1223/5627_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
CCL15-CCL14 | CCL15-CCL14 readthrough (NMD candidate) | Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CDO1 | Cysteine dioxygenase type 1 | Enzymes
| | ![](/images/36573/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/57503/137455_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
CFH | Complement factor H | Cancer-related genes Disease related genes Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/38922/103209_A_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
CFI | Complement factor I | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| ![](/images/16777/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/1143/2463_B_2_5_rna_selected_60x60.jpg) | Tissue enhanced |
CHRNA4 | Cholinergic receptor, nicotinic, alpha 4 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| ![](/images/34064/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/34064/70739_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
CLDN1 | Claudin 1 | Disease related genes Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/48319/122919_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
COLEC11 | Collectin sub-family member 11 | Disease related genes Plasma proteins Predicted secreted proteins
| ![](/images/35241/ihc_selected_60x60.jpg) | ![](/images/35241/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/35241/72127_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
CRHBP | Corticotropin releasing hormone binding protein | Plasma proteins Predicted secreted proteins
| ![](/images/46120/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46120/103112_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
CTH | Cystathionase (cystathionine gamma-lyase) | Disease related genes Enzymes Potential drug targets
| | | ![](/images/23300/ihc_cell_selected_60x60.jpg) | ![](/images/21591/51666_B_9_7_rna_selected_60x60.jpg) | Tissue enhanced |
CXCL2 | Chemokine (C-X-C motif) ligand 2 | Cancer-related genes Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CYP27A1 | Cytochrome P450, family 27, subfamily A, polypeptide 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets
| ![](/images/59155/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/59155/141443_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
CYP2C18 | Cytochrome P450, family 2, subfamily C, polypeptide 18 | Enzymes Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CYP2C19 | Cytochrome P450, family 2, subfamily C, polypeptide 19 | Cancer-related genes Enzymes Plasma proteins Predicted secreted proteins
| ![](/images/15066/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/15066/34421_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
CYP2J2 | Cytochrome P450, family 2, subfamily J, polypeptide 2 | Enzymes Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CYP39A1 | Cytochrome P450, family 39, subfamily A, polypeptide 1 | Enzymes Predicted membrane proteins
| ![](/images/29892/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/29892/61678_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |